Comparison of the tolerability of ¹⁶¹Tb- and ¹⁷⁷Lu-labeled somatostatin analogues in the preclinical setting.

ABSTRACT:

Purpose

[¹⁷⁷Lu]Lu-DOTATATE is an established somatostatin receptor (SSTR) agonist for the treatment of metastasized neuroendocrine neoplasms, while the SSTR antagonist [¹⁷⁷Lu]Lu-DOTA-LM3 has only scarcely been employed in clinics. Impressive preclinical data obtained with [¹⁶¹Tb]Tb-DOTA-LM3 in tumor-bearing mice indicated the potential of terbium-161 as an alternative to lutetium-177. The aim of the present study was to compare the tolerability of ¹⁶¹Tb- and ¹⁷⁷Lu-based DOTA-LM3 and DOTATATE in immunocompetent mice.

Methods

Dosimetry calculations were performed based on biodistribution data of the radiopeptides in immunocompetent mice. Treatment-related effects on blood cell counts were assessed on Days 10, 28 and 56 aft

SUBMITTER: Busslinger SD 

PROVIDER: S-EPMC11527941 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature